Molecular Switch Controlling Immune Suppression May Help Turn Up Immunotherapies
September 20, 2016
Untreated: Hepatitis C, America’s Prison Epidemic
September 21, 2016
Show all

Novartis Drug for Multiple Sclerosis Shows Reduction in Risks

An experimental drug for those with a severe form of multiple sclerosis reduced the risk of the disease progressing by 21 percent, according to new research.

Swiss drugmaker Novartis AG said its experimental medicine for people with a severe form of multiple sclerosis could be a blockbuster after a study showed that the treatment reduced the risk of the disease progressing by 21 percent.

The oral drug siponimod could be prescribed for patients with a highly disabling form of multiple sclerosis for which there are very few treatment options, Novartis said in a statement on Saturday. The company in August said the drug met its target for reducing the risk of the disability progression in a late-stage study.

“This population hasn’t had an effective therapy,” Vasant Narasimhan, chief medical officer for Novartis, said in a phone interview. “For the first time, we have a medicine that can slow the progression of this disease in a proportion of these patients, so we view it as a significant breakthrough.”

Read Full Article: Novartis Drug for Multiple Sclerosis Shows Reduction in Risks – Bloomberg

Read Full Article: Novartis Drug for Multiple Sclerosis Shows Reduction in Risks – Bloomberg

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.